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Abstract
The study aim was to describe the emergence of carbapenem
resistance and clonal complexes (CC), deﬁned by multilocus
sequence typing (MLST), in Acinetobacter baumannii in a surveil-
lance system for meningitis. Starting in 1996 in an urban setting of
Brazil, surveillance detected meningitis by Acinetobacter sp for the
ﬁrst time in 2002. Up to 2008, 35 isolates were saved.
Carbapenem resistance emerged in 2006, reaching 70% of
A. baumannii isolates in 2008, including one that was colistin
resistant. A. baumannii belonged to CC113/79 (University of
Oxford/Institute Pasteur schemes), CC235/162 and CC103/15.
Dissemination of infections resistant to all antimicrobial agents
may occur in the future.
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Acinetobacter baumannii has become increasingly recognized as
a cause of multidrug-resistant central nervous system infec-
tions [1]. A. baumannii clones are classiﬁed by multilocus
sequence typing (MLST) by protocols hosted at Institut Pasteur
(IP, www.pasteur.fr) and the University of Oxford (UO, www.
pubmlst.org), and grouped into clonal complexes (CCs).
Typing an isolate by both schemes is useful as there is no
link between IP and UO databases. To date, little is known
about the population structure of A. baumannii from cases of
meningitis worldwide [2]. In 1996, a hospital-based active-
surveillance for bacterial meningitis was established at Hospital
Couto Maia, a state infectious disease reference hospital in
Salvador, Brazil [3]. The main purpose of this system was to
investigate classical pathogens Haemophilus inﬂuenzae, Neisseria
meningitidis and Streptococcus pneumoniae. Non-classical agents
were also sought because all CSF specimens from public
hospitals in the city are processed at this hospital. The aim of
the present study was to describe the emergence of carba-
penem resistance in Acinetobacter spp and the distribution of
A. baumannii CCs in isolates recovered from meningitis in this
system. A case of culture-proven bacterial meningitis was a patient
with typical symptoms and Acinetobacter sp isolated from CSF.
From 2002 to 2008, 57 cases of hospital-acquired Acinetobacter sp
meningitisweredetected;35 isolates (oneperpatient)weresaved.
Species were identiﬁed by sequence analysis of 350-bp rpoB gene
fragments [4] anddeﬁnedby at least97% similaritywithone in a set
of reference strains and by BLAST [5].
Antimicrobial susceptibility was determined by disk diffusion
[6] for: amikacin, gentamicin, tobramycin, ampicillin-sulbactam,
cefepime, ceftazidime, ciproﬂoxacin, imipenem, meropenem,
minocycline, tetracycline, piperacillin-tazobactam and trimeth-
oprim-sulphamethoxazole. Minimum inhibitory concentrations
(MICs) of cefepime, imipenem, meropenem and tigecycline
were deﬁned by Etest following the manufacturer’s instruc-
tions (bioMerieux, Solna, Sweden). Colistin MICs were deter-
mined by broth microdilution [7]. Susceptibility to all agents
was interpreted as recommended by CLSI [8], except for
tigecycline, interpreted as proposed by the US Food and Drug
Administration (FDA) for Enterobacteriaceae. Isolates were
classiﬁed as multidrug-resistant (MDR) or extensively
drug-resistant (XDR) [9]. Metallo-b-lactamase production
was screened by a double-disk test [10]. The following
carbapenemase encoding genes were investigated by
PCR: blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like,
blaOXA-143, blaKPC, blaNDM, blaGIM-1, blaIMP-type, blaSIM-1,
blaSPM-1, blaVIM-type, blaCTX-M-1, blaCTX-M-2, blaCTX-M-8, blaCTX-M-9
and blaCTX-M-25 [11–15]. Isolates were typed by pulsed-ﬁeld
gel electrophoresis (PFGE) [16] and included within a pulso-
type if band proﬁles had  5 differences. UO and IP MLST
schemes were performed [17,18]. CCs were formed by STs
with ﬁve or more identical alleles by goeBURST (goe-
burst.phyloviz.net). STs and CCs are here referred by the
UO/IP scheme.
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From 2001 to 2008, 1398 meningitis cases were detected
among c.3000 patients, and 931 (67%) were caused by classical
agents. Acinetobacter sp, identiﬁed for the ﬁrst time in 2002,
increased signiﬁcantly (R2 = 0.94) from 0.9% in 2001–2002 to
4.3% in 2007–2008. The median age of patients was 25  21.3
(range 3–82) years and 71.4% were men. From 57 stored
Acinetobacter spp isolates (one per patient), 35 (61%) were
available for further characterization. Most (31) were
A. baumannii, two Acinetobacter nosocomialis, and one each
Acinetobacter ursingii and Acinetobacter genomic species 15TU.
Non-A. baumannii isolates were susceptible to all drugs or
resistant only to sulphamethoxazole-trimethoprim. All A. bau-
mannii isolates were susceptible to minocycline and tigecycline.
One isolate from 2008 was colistin resistant (MIC = 64 mg/L),
FIG. 1. Temporal distribution of Acinetobacter baumannii clonal complexes (CCs) and carbapenem-resistant A. baumannii isolates over 7 years of
study. ‘Others’ include single pulsotypes and one not typeable isolate not selected for MLST analysis. CCs are described according to University of
Oxford/Institute Pasteur schemes.
TABLE 1. Characteristics of Acinetobacter baumannii isolates from 31 patients with meningitis
MLST-UO MLST-IP Characteristic (number of isolates)
CC
ST (isolates
sequenced) CC
ST (isolates
sequenced) Pulsotype blaOXA-23 Susceptibility phenotype
113 237a (2) 79 79 (5) A (6) + (3) COL MIN TET TGC TOB (1)
COL MIN TGC TOB (1)
MIN TET TGC TOB (1)
258a (1) + (1) COL MIN TET TGC TOB (1)
259a (1)  (1) AMS COL GEN IPM MEM MIN TET TGC TOB (1)
233a (1)  (1) AMS COL GEN IPM MEM MIN TET TGC TOB (1)
235 235a (3) 162 162a (4) B (6) + (3) COL MIN TET TGC (1)
COL MIN TGC (2)
 (1) AMI AMS COL GEN IPM MEM MIN SXT TGC TOB (1)
415a (1) + (2) COL MIN TET TGC (1)
COL MIN TGC (1)
416a (1) 163a (1) L (1) + (1) AMS COL GEN MIN TET TGC TOB (1)
103 236a (1) 15 15 (1) C (4) + (4) COL GEN MIN TET TGC TOB (1)
COL MIN TET TGC (1)
COL MIN TGC (2)
234 234a (2) NA 164a,b (3) D (3)  (3) AMS CIP COL FEP IPM MEM MIN PTZ TET TGC (1)
AMS COL IPM MEM MIN TET TGC (1)
232a (1) AMS CIP COL FEP IPM MEM MIN PTZ TET TGC (1)
ND ND ND ND E – K, M – N (9)  (9) Variousc
O (1) + (1) AMS COL MIN TGC TOB (1)
Not typeable (1) + (1) AMI AMS CAZ COL GEN MIN SXT TGC TOB (1)
CC, clonal complex; ST, sequence type; NA, not assigned; ND, not determined; AMI, amikacin; AMS, ampicillin-sulbactam; CAZ, ceftazidime; CIP, ciproﬂoxacin; COL, colistin; FEP,
cefepime; GEN, gentamicin; IPM, imipenem; MEM, meropenem; MIN, minocycline; PTZ, piperacillin-tazobactam; SXT, trimethoprim-sulphamethoxazole; TET, tetracycline; TGC,
tigecycline; TOB, tobramycin.
aST described in the present study.
bST164 was not assigned to either clonal complex because this one is DLV of other published ST.
cIncludes susceptibility to all drugs (three isolates); one isolate each of AMI AMS CAZ CIP COL FEP GEN IPM MEM MIN PTZ TET TGC TOB, AMS CIP COL FEP IPM MEM MIN
TET TGC, COL GEN IPM MEM MIN TET TGC TOB, COL CIP IPM MEM MIN TET TGC TOB, AMS COL IPM MEM MIN TGC and COL IPM MEM MIN TET TGC.
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and susceptible only to minocycline, tetracycline, tigecycline
and tobramycin. MICs50/MICs90 were 32/>256 mg/L for cefe-
pime, 1/>32 mg/L for imipenem, 4/>32 mg/L for meropenem,
0.5/1 mg/L for colistin and 0.38/1 mg/L for tigecycline. Thir-
teen A. baumannii isolates were MDR and 14 XDR. Carbape-
nem resistance emerged in May 2006 and became endemic
(Fig. 1). All carbapenem-resistant isolates carried the blaOXA-
23-like gene and the natural blaOXA-51-like gene, detected in all
A. baumannii isolates. blaCTX-M-2 was detected in one MDR
A. baumannii from 2004. No other carbapenemase-encoding
gene or metallo-b-lactamase production was observed.
Acinetobacter baumannii formed 15 pulsotypes, and one
isolate was not typeable. Nineteen of 30 typeable A. bau-
mannii isolates were included in four pulsotypes (A–D).
Fourteen isolates of main pulsotypes were selected for MLST.
Ten STs (all new) were identiﬁed by the UO scheme and ﬁve
(three new) by the IP scheme (Table 1). STs formed four
CCs by UO, and three by the IP scheme, unrelated to
international clones I, II and III. ST164 by the IP scheme was
not assigned to a CC because this is a double locus variant
(DLV) of just one other ST. Each of the seven CCs was
isolated over more than 20 months during the 6 years of
surveillance (Fig. 1). CC113/79 included the colistin-resistant
isolate (ST237/79). Although 22 of the 57 cases detected in
the surveillance system could not have the species deter-
mined, we believe all these cases were indeed caused by the
genus Acinetobacter because such identiﬁcation is simple. No
further data about Acinetobacter infections in the study
hospital are available; however, these infections are likely to
be part of hospital dissemination of this pathogen, previously
noted in Brazil [19].
Carbapenem resistance was ﬁrst detected by the system in
2006 and increased over time to affect 16 of the 31 study
A. baumannii isolates, associated with the presence of the
blaOXA-23 gene. Alarmingly, 14 of A. baumannii isolates were
XDR. High susceptibility to colistin, minocycline and tigecy-
cline was observed. Colistin has been recommended for
meningitis caused by carbapenem-resistant A. baumannii [20],
but resistance should become increasingly frequent. Use of
tigecycline has been described as effective in a few case reports
[20]; however, the pharmacodynamic proﬁle of this drug does
not seem adequate for this purpose [20].
CC113/79, CC235/162 and CC103/15 were important
causes of meningitis in the present study and prone to develop
resistance to multiple agents. Except for the ATCC 17978
strain, no other isolate from patients with meningitis could be
related to the CCs of the present study. This ﬁnding suggests
that meningitis is not caused preferentially by isolates with a
speciﬁc tropism for the central nervous system, but by clones
circulating in hospitals.
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